2023
DOI: 10.1038/s41565-022-01310-1
|View full text |Cite|
|
Sign up to set email alerts
|

Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
41
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 54 publications
(42 citation statements)
references
References 51 publications
1
41
0
Order By: Relevance
“…Bottlebrush polymers (BBPs) have attracted considerable interest due to their unique properties originating from chain architecture and have found a wide range of applications, such as super-soft elastomers, nanomedicine, , electronics, and self-healing materials . Recently, cyclic BBPs have emerged as a very interesting material.…”
Section: Introductionmentioning
confidence: 99%
“…Bottlebrush polymers (BBPs) have attracted considerable interest due to their unique properties originating from chain architecture and have found a wide range of applications, such as super-soft elastomers, nanomedicine, , electronics, and self-healing materials . Recently, cyclic BBPs have emerged as a very interesting material.…”
Section: Introductionmentioning
confidence: 99%
“…38) that affords multivalent norbornene imide in extremely high yield, high efficiency, and simplicity, 289 achieving the establishment of a modular, scalable, and well-defined bottlebrush prodrug (BPD) platform. 263–265,290–295…”
Section: Polymers From Bicyclic Alkenesmentioning
confidence: 99%
“…Isolating activation kinetics as a key variable, however, requires a prodrug platform capable of generating multiple physically equivalent TLR agonist prodrugs that only vary by their activation kinetics, which is traditionally very challenging and has, so far, not been explored in the context of immune stimulation. We have created "bottlebrush prodrugs" (BPDs), which are a class of polymers that feature drug molecules covalently linked along their rigid backbones with PEG chains that extend from the backbone to shield the drugs from surface exposure (30)(31)(32). These structures offer unique advantages for controlled delivery, particularly for studying the impact of release kinetics on biological functions, as they can be easily manufactured with a variety of prodrug linkers while maintaining identical sizes, shapes, biodistribution, serum pharmacokinetics (PKs), and other key physical properties.…”
Section: Introductionmentioning
confidence: 99%